

# Company Heartbeats

**Swiss companies** - Position yourself with UBS Warrants for upcoming financial results

Company Heartbeats regularly lists companies that will soon present their financial results and for which UBS is offering suitable Warrants. The Warrants are listed on the SIX Structured Products Exchange and tradable on every trading day under normal market conditions. Please consider the disclaimer at the end of this document.

Date	Company	Publication	Share price	Suitable Warrants						
				Type	SIX symbol	Expiry	Leverage	Strike	Ask price	More Warrants
21 Oct 24	DocMorris	Q3 result	CHF 31.66	Call	<a href="#">UC4SOU</a>	21 Mar 25	3.52	34.00	0.09	<a href="#">Calls on DocMorris</a>
21 Oct 24	Logitech	Semi-annual report	CHF 77.04	Call	<a href="#">9LOGWU</a>	21 Mar 25	7.22	80.00	0.24	<a href="#">Calls on Logitech</a>
				Put	<a href="#">UBB9SU</a>	21 Mar 25	6.32	75.00	0.25	<a href="#">Puts on Logitech</a>
23 Oct 24	Temenos Group	Q3 result	CHF 64.00	Call	<a href="#">ZUBS1U</a>	21 Mar 25	4.92	66.00	0.26	<a href="#">Calls on Temenos Group</a>
23 Oct 24	Kuhne&Nagel	Q3 result	CHF 226.40	Call	<a href="#">UBBSGU</a>	21 Mar 25	8.38	240.00	0.20	<a href="#">Calls on Kuhne&amp;Nagel</a>
25 Oct 24	BB Biotech	Q3 result	CHF 37.60	Call	<a href="#">QBIOKU</a>	21 Mar 25	7.31	40.00	0.06	<a href="#">Calls on BB Biotech</a>
28 Oct 24	SIG Combibloc	Q3 result	CHF 18.62	Call	<a href="#">KSIG3U</a>	21 Mar 25	8.61	20.00	0.10	<a href="#">Calls on SIG Combibloc</a>
28 Oct 24	Bucher Ind.	Q3 result	CHF 369.00	Call	<a href="#">GBUC1U</a>	21 Mar 25	9.06	400.00	0.11	<a href="#">Calls on Bucher Ind.</a>
28 Oct 24	Ems	Q3 result	CHF 686.50	Call	<a href="#">U1SS5U</a>	21 Mar 25	9.15	750.00	0.06	<a href="#">Calls on Ems</a>
29 Oct 24	Idorsia	Q3 result	CHF 1.20	Call	<a href="#">B68SGU</a>	21 Mar 25	1.74	1.30	0.08	<a href="#">Calls on Idorsia</a>
29 Oct 24	Clariant	Q3 result	CHF 12.53	Call	<a href="#">UY6SEU</a>	21 Mar 25	8.56	13.00	0.12	<a href="#">Calls on Clariant</a>
29 Oct 24	Novartis	Q3 result	CHF 101.06	Call	<a href="#">UOB7SU</a>	21 Mar 25	13.47	105.00	0.19	<a href="#">Calls on Novartis</a>
				Put	<a href="#">SUIZBU</a>	21 Mar 25	12.41	95.00	0.19	<a href="#">Puts on Novartis</a>
30 Oct 24	Burckardt Comp.	Semi-annual report	CHF 640.00	Call	<a href="#">UNBSDU</a>	21 Mar 25	5.56	700.00	0.19	<a href="#">Calls on Burckardt Comp.</a>

Source: Refinitiv, UBS.

As of: 18 Oct 24. All prices are indicative.

# Company Heartbeats

**International companies** - Position yourself with UBS Warrants for upcoming financial results

Company Heartbeats regularly lists companies that will soon present their financial results and for which UBS is offering suitable Warrants. The Warrants are listed on the SIX Structured Products Exchange and tradable on every trading day under normal market conditions. Please consider the disclaimer at the end of this document.

Date	Company	Publication	Share price	Suitable Warrants						
				Type	SIX symbol	Expiry	Leverage	Strike	Ask price	More Warrants
21 Oct 24	SAP	Q3 result	EUR 210.40	Call	<a href="#">RSAPZU</a>	21 Mar 25	8.42	220.00	0.23	<a href="#">Calls on SAP</a>
23 Oct 24	Dt.Bank	Q3 result	EUR 16.25	Call	<a href="#">TUBSRU</a>	21 Mar 25	6.95	17.00	0.26	<a href="#">Calls on Dt.Bank</a>
23 Oct 24	Tesla	Q3 result	USD 220.89	Call	<a href="#">TSAMDU</a>	21 Mar 25	5.08	230.00	0.47	<a href="#">Calls on Tesla</a>
24 Oct 24	Amazon	Q3 result	USD 187.53	Call	<a href="#">PKUBSU</a>	21 Mar 25	7.78	195.00	1.23	<a href="#">Calls on Amazon</a>
29 Oct 24	Alphabet	Q3 result	USD 164.51	Call	<a href="#">SBUNOU</a>	21 Mar 25	8.07	170.00	0.52	<a href="#">Calls on Alphabet</a>
29 Oct 24	AMD	Q3 result	USD 156.25	Call	<a href="#">UWBKSU</a>	21 Mar 25	5.36	170.00	0.70	<a href="#">Calls on AMD</a>
29 Oct 24	Lufthansa	Q3 result	EUR 6.82	Call	<a href="#">LUBSGU</a>	21 Mar 25	7.96	7.50	0.06	<a href="#">Calls on Lufthansa</a>
30 Oct 24	Meta Platforms	Q3 result	USD 576.93	Call	<a href="#">MET93U</a>	21 Mar 25	6.54	600.00	0.90	<a href="#">Calls on Meta Platforms</a>
30 Oct 24	Microsoft	Q1 result	USD 416.72	Call	<a href="#">PZUBSU</a>	21 Mar 25	9.47	430.00	0.44	<a href="#">Calls on Microsoft</a>
30 Oct 24	Eli Lilly	Q3 result	USD 917.12	Call	<a href="#">00UBSU</a>	21 Mar 25	6.88	950.00	0.68	<a href="#">Calls on Eli Lilly</a>
30 Oct 24	Paypal	Q3 result	USD 79.82	Call	<a href="#">UTOSCU</a>	21 Mar 25	6.97	85.00	0.11	<a href="#">Calls on Paypal</a>
30 Oct 24	Volkswagen	Q3 result	EUR 92.46	Call	<a href="#">URGS8U</a>	21 Mar 25	8.55	100.00	0.08	<a href="#">Calls on Volkswagen</a>

Source: Refinitiv, UBS.

As of: 18 Oct 24. All prices are indicative.

## Disclaimer

This material has been prepared by UBS AG or one of its affiliates ("UBS"). This material is only intended for the distribution permitted under the applicable law. It has not been prepared for the needs of a specific recipient. It is only published for information purposes and does not constitute an offer or an invitation to purchase or sell securities or associated financial instruments ("Instruments"). UBS accepts no liability (either expressly or tacitly) for the completeness or reliability of the information contained in this document, except for the information on UBS AG and its affiliates. The information should not be regarded by the recipients as a substitute for their own judgment. All the opinions contained herein may change without prior notice and contradict the opinions of other business areas of UBS due to the application of different assumptions and criteria. UBS is not obliged to keep the information up to date. UBS, its executives, employees or clients may have or have had a participation in the Instruments and may conclude transactions with them at any time. UBS may maintain or have maintained a relationship with the entities specified in this information. Neither UBS nor its affiliates, executives or employees are liable for losses resulting from the use of this information.

**Structured derivatives do not constitute participation in collective investment schemes. For this reason they do not require approval from the Swiss Financial Market Supervisory Authority (FINMA). As a result, investors are not entitled to the specific investor protection provided by the Swiss Collective Investment Schemes Act (CISA).**

Structured products are complex and involve a high risk. The intrinsic value of the investment instruments depends not only on the performance of the underlying asset, but also on the issuer's creditworthiness (credit risk), which can change over the duration of the product. In relation to any securities, currencies, financial instruments or other assets underlying a transaction to which this material relates, the values may fall as well as rise and past performance is not an indication of future performance. Before entering into any transaction, you should consult your own legal, supervisory, tax, financial and accounting advisors as you consider necessary. You should also make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) at your own discretion and based on your consultation with advisors as you consider necessary. Unless expressly agreed otherwise in writing, UBS does not act as financial advisor or fiduciary in any transaction. The terms and conditions of an investment are subject solely to the detailed provisions, including risk considerations, contained in the relevant product documentation. The product documentation, i.e. the prospectus and the Key Information Document (KID), can be obtained from the website [keyinvest.ch/en.ubs.com](https://keyinvest.ch/en.ubs.com), by entering the relevant security / ISIN. Before you invest in a product, please read the current prospectus and the Key Information Document (KID) carefully and thoroughly. UBS makes no representations or warranties with regard to any information contained herein, which originates from independent sources. This publication may not be copied or reproduced without UBS's prior written permission.

Not for distribution in the United States or to US persons. © UBS 2024. All rights reserved. The key symbol and UBS are among the registered and unregistered trademarks of UBS. UBS prohibits the forwarding of this information without the approval of UBS.

## Contact

[keyinvest@ubs.com](mailto:keyinvest@ubs.com)

+41 44 239 76 76\*

[ubs.com/keyinvest](https://ubs.com/keyinvest)

\*Please note that calls to numbers marked with \* may be recorded. When you call these numbers, we assume that you consent to this practice.